Cited by 787Schizophrenia research and treatmentMental Health and PsychiatryBipolar Disorder and Treatment

The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.

Neuroleptics and the Natural Course of Schizophrenia

Wyatt, R. J.·1991·Schizophrenia Bulletin

Open this paper in CoChat — free account

Abstract

To determine if neuroleptic treatment changes the natural course of schizophrenia, 22 studies were reviewed in which relatively similar patients were or were not given neuroleptics at specific times during the course of their illness. Nineteen of the studies were from first- or predominantly first-break populations. While there was little consensus among the authors of the studies reviewed, a reanalysis of the data indicates that early intervention with neuroleptics in first-break schizophrenic patients increases the likelihood of an improved long-term course. This finding is similar to that of earlier investigators who indicated there was a decrease in patients with the more severe forms of the illness following the introduction of convulsive therapies. Furthermore, there is evidence that stable schizophrenic patients whose neuroleptics are discontinued and have relapses may have a difficult time returning to their previous level of function. The findings describe in this paper have implications for both the treatment of schizophrenia and for understanding the pathophysiological processes that determine the course of the disorder.

Integrity signals

Registry

Crossref · 10.1093/schbul/17.2.325

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Statistical principles in experimental design.
Winer, B. J. (1962) · McGraw-Hill Book Company · doi:10.1037/11774-000 · Cited by 27,137
Dementia Praecox or the Group of Schizophrenias
(1951) · Journal of the American Medical Association · doi:10.1001/jama.1951.02920270079043 · Cited by 4,407
Dementia Praecox and Paraphrenia.
(1972) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-6-1058_8 · Cited by 2,907
Statistical Methods for Survival Data Analysis.
Lachenbruch, P. A., & Lee, E. T. (1993) · Journal of the American Statistical Association · doi:10.2307/2290742 · Cited by 2,851
International Classification of Diseases, 10th Revision
Tassé, M. J., & Bush, K. (2018) · Sage eBooks · doi:10.4135/9781483392271.n276 · Cited by 1,921
Drug and Family Therapy in the Aftercare of Acute Schizophrenics
Goldstein, M. J. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770340019001 · Cited by 521
II. A Randomised Controlled Trial of Prophylactic Neuroleptic Treatment
Crow, T. J., Macmillan, J. F., Johnson, A. L., & Johnstone, E. C. (1986) · The British Journal of Psychiatry · doi:10.1192/bjp.148.2.120 · Cited by 491
Schizophrenia, just the facts
Wyatt, R. J., Alexander, R., Egan, M. F., & Kirch, D. G. (1988) · Schizophrenia Research · doi:10.1016/0920-9964(88)90034-5 · Cited by 478
Self-citation
Neuropathology of Schizophrenia
Stevens, J. R. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290100011003 · Cited by 474
Longitudinal Studies of Schizophrenic Patients
Huber, G., Gross, G., Schüttler, R., Linz, M. H., & Clemens, S. L. (1980) · Schizophrenia Bulletin · doi:10.1093/schbul/6.4.592 · Cited by 439

Show all 73 references

Sorted by citations

Items 401–500 of 787

Is earlier better? At the beginning of schizophrenia: timing and opportunities for early intervention.
Clarke, M., & O'Callaghan, E. (2003) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(02)00036-9 · Cited by 21
New Directions in the Prevention and Treatment of Schizophrenia: A Biological Perspective
Wyatt, R. J., Apud, J. A., & Potkin, S. G. (1996) · Psychiatry · doi:10.1080/00332747.1996.11024774 · Cited by 21
Self-citation
Neurodevelopmental and neurodegenerative hypotheses of schizophrenia: a review and critique
McClure, R. K., & Lieberman, J. A. (2003) · Current Opinion in Psychiatry · doi:10.1097/00001504-200304002-00004 · Cited by 22
Early Detection and Management of Mental Disorders
Maj, M. (2004) · Wiley eBooks · doi:10.1002/0470010851 · Cited by 32
Long-Acting Injectable Aripiprazole
Gopalakrishna, G., Aggarwal, A., & Lauriello, J. (2013) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.goag.043013 · Cited by 20
Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
Parellada, E., Velligan, D. I., Emsley, R. A., & Kissling, W. (2012) · Schizophrenia Research and Treatment · doi:10.1155/2012/318535 · Cited by 20
The management of schizophrenia: focus on extended-release quetiapine fumarate
Peuskens, J. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s3380 · Cited by 20
Executive function in schizophrenia: Influence of substance use disorder history
Rodríguez–Jiménez, R., Bagney, A., Martínez‐Gras, I., Ponce, G., Sánchez‐Morla, E. M., Aragüés, M., Rubio, G., Jiménez‐Arriero, M. Á., Santos, J. L., & Palomo, T. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.09.025 · Cited by 20
Impact of early use of long-acting injectable antipsychotics on psychotic relapses and hospitalizations in first-episode psychosis
Abdel‐Baki, A., Medrano, S., Maranda, C., Ladouceur, M., Tahir, M. R., Stip, É., & Potvin, S. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000310 · Cited by 20
Examining Adherence to Medication and Substance Use as Possible Confounds of Duration of Untreated Psychosis
Norman, R. M. G., & MALLA, A. K. (2002) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-200205000-00010 · Cited by 20
The impact of the duration of untreated psychosis on short- and long-term outcome in schizophrenia
Ronald Bottlender, A., & Möller, H. (2003) · Current Opinion in Psychiatry · doi:10.1097/00001504-200304002-00007 · Cited by 20
Taking cognizance of mental illness in schizophrenics and its association with crime and substance‐related diagnoses
Munkner, R., Haastrup, S., Jørgensen, T., Andreasen, A. H., & Kramp, P. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2003.02122.x · Cited by 21
Prescribing pattern of clozapine and other antipsychotics for patients with first-episode psychosis: a cross-sectional survey of early intervention teams
Tungaraza, T. E., Ahmed, W., Chira, C., Turner, E., Mayaki, S., Nandhra, H. S., Edwards, T., & Farooq, S. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316683151 · Cited by 20
Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison
Crespo‐Facorro, B., Pérez‐Iglesias, R., Mata, I. F., Ramírez-Bonilla, M., Martínez‐García, O., Pardo‐García, G., Caseiro, O., Pelayo‐Terán, J. M., & Vázquez‐Barquero, J. L. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110388332 · Cited by 19
The Dynamics of Insight in the Prodrome of Schizophrenia
Bota, R. G., Munro, J. S., Ricci, W. F., & Bota, D. A. (2006) · CNS Spectrums · doi:10.1017/s1092852900014486 · Cited by 19
Applications of pharmacogenetics in psychiatry: personalisation of treatment
Arranz, M. J., Munro, J., Osborne, S., Collier, D. A., & Kerwin, R. W. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.4.537 · Cited by 19
Primary Prevention in Geriatric Psychiatry
Madhusoodanan, S., Ibrahim, F., & Malik, A. (2010) · Annals of Clinical Psychiatry · doi:10.1177/104012371002200404 · Cited by 18
Schizophrenia in late life: Aging effects on symptoms and course of illness.
Harvey, P. D. (2005) · American Psychological Association eBooks · doi:10.1037/10873-000 · Cited by 18
Clozapine: Current Status and Role in the Pharmacotherapy of Schizophrenia
Remington, G. J., Addington, D. E., Collins, E. J., Jones, B., Lalonde, P., MacCrimmon, D. J., & MacEwan, G. W. (1996) · The Canadian Journal of Psychiatry · doi:10.1177/070674379604100306 · Cited by 18
Evaluating the utility of digital phenotyping to predict health outcomes in schizophrenia: protocol for the HOPE-S observational study
Rashid, N. A. A., Martanto, W., Yang, Z., Wang, X., Heaukulani, C., Vouk, N., Buddhika, T., Wei, Y., Verma, S. K., Tang, C. Y. Z., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-046552 · Cited by 18
The role of BDNF and NGF plasma levels in first-episode schizophrenia: A longitudinal study
Martínez-Pinteño, A., Mezquida, G., Bioque, M., López-Ilundain, J. M., Andreu-Bernabeu, Á., Zorrilla, E. P., Mané, A., Rodríguez–Jiménez, R., Corripio, I., Sarró, S., et al. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.02.003 · Cited by 18
The need for E xperience F ocused C ounselling ( EFC ) with voice hearers in training and practice: a review of the literature
Schnackenberg, J., & Martin, C. R. (2013) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/jpm.12084 · Cited by 17
Predictors of cognition in first episode psychosis
Lutgens, D., Lepage, M., Iyer, S. N., & MALLA, A. K. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.10.044 · Cited by 17
Experience of quality of life and attitude to care and treatment in patients with schizophrenia: Role of cross-sectional remission
Helldin, L., Kane, J. M., Karilampi, U., Norlander, T., & Archer, T. (2008) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500701660007 · Cited by 17
Gender differences in one‐year outcomes of first‐presentation psychosis patients in inner‐city UK E arly I ntervention S ervices
Tseliou, F., Johnson, S., Major, B., Rahaman, N., Joyce, J., Lawrence, J., Mann, F., Tapfumaneyi, A., Chisholm, B., Chamberlain‐Kent, N., et al. (2015) · Early Intervention in Psychiatry · doi:10.1111/eip.12235 · Cited by 17
Prevalence and incidence of schizophrenia spectrum disorders: implications for prevention
Jablensky, A. V. (2000) · Australian & New Zealand Journal of Psychiatry · doi:10.1046/j.1440-1614.2000.00770.x · Cited by 17
Early Intervention and Sustaining the Management of Vulnerability
Birchwood, M. J. (2000) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/000486740003401s27 · Cited by 17
Why Neuroleptic Withdrawal in Schizophrenia?
Carpenter, W. T. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150024003 · Cited by 17
Qualitätssicherung diagnostischer und therapeutischer Maßnahmen im psychiatrischen Krankenhaus
Gäebel, W. (1995) · Springer eBooks · doi:10.1007/978-3-7091-9386-0_10 · Cited by 17
Un enfoque empírico de la recuperación de la esquizofrenia: definir la recuperación e identificar los factores que pueden facilitarla
Liberman, R. P., & Kopelwicz, A. (2004) · Cited by 15
Intervention précoce pour la psychose : concepts, connaissances actuelles et orientations futures
Iyer, S. N., & MALLA, A. K. (2014) · Santé mentale au Québec · doi:10.7202/1027840ar · Cited by 16
Ethical concerns in schizophrenia research: looking back and moving forward.
Wilson, S. T., & Stanley, B. (2005) · Schizophrenia bulletin · doi:10.1093/schbul/sbj023 · Cited by 18
Attitude towards Antipsychotic Medications in Patients Diagnosed with Schizophrenia: A Cross-Sectional Study at Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia
Kassew, T., Demilew, D., Birhanu, A., Wonde, M., Liyew, B., & Shumet, S. (2019) · Schizophrenia Research and Treatment · doi:10.1155/2019/5094017 · Cited by 16
Treatment of the Schizophrenia Prodrome
Cornblatt, B. A., Lencz, T., Smith, C. W., & Auther, A. M. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-729-1_14 · Cited by 15
Psychisch kranke Rechtsbrecher
Leygraf, N. (2006) · Steinkopff eBooks · doi:10.1007/3-7985-1633-2_8 · Cited by 16
Cerebrospinal fluid and serum levels of neuron-specific enolase in patients with schizophrenia
Egan, M. F., El‐Mallakh, R. S., Suddath, R. L., Lohr, J. B., Bracha, H. S., & Wyatt, R. J. (1992) · Psychiatry Research · doi:10.1016/0165-1781(92)90133-n · Cited by 16
Self-citation
Parents’ Experience of Their Child's First Psychiatric Breakdown: “Welcome to Hell”
Shpigner, E., Possick, C., & Buchbinder, E. (2013) · Social Work in Health Care · doi:10.1080/00981389.2013.780835 · Cited by 19
Comparison of characteristics between geriatric and younger subjects with schizophrenia in community
Ran, M., Xiang, M., Conwell, Y., Lamberti, J. S., Huang, M., Shan, Y.-H., & Hu, X. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2003.12.003 · Cited by 15
Development of a Boston Treatment Program for Youth at Clinical High Risk for Psychosis: Center for Early Detection, Assessment, and Response to Risk (CEDAR)
Friedman‐Yakoobian, M. S., West, M. L., Woodberry, K. A., O’Donovan, K., Zimmet, S. V., Gnong-Granato, A., Giuliano, A. J., Guyer, M. E., Rodenhiser, J., Keshavan, M. S., et al. (2018) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000181 · Cited by 15
Chronic Late-Onset Schizophrenia-Like Psychosis That Remitted: Revisiting Newton’s Psychosis?
Jeste, D. V., Harless, K., & Palmer, B. W. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.3.444 · Cited by 15
Long-term Treatment for Lifetime Disorders?
Greden, J. F. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150029004 · Cited by 15
Neuroleptic effects on serine and glycine metabolism
Baruah, S., Waziri, R., & Sherman, A. D. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90197-l · Cited by 15
Diagnosis, Treatment, and Six-Month Outcome Status in First-Admission Psychosis
Craig, T., Bromet, E. J., Jandorf, L. H., Fennig, S., Tanenberg‐Karant, M., Ram, R., & Rosen, B. (1997) · Annals of Clinical Psychiatry · doi:10.1023/a:1026205319204 · Cited by 15
The Early Course of Schizophrenia and Long-term Maintenance Neuroleptic Therapy
Nuechterlein, K. H. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150035006 · Cited by 15
Evaluating the Importance of Reducing the Duration of Untreated Psychosis
McGorry, P. D. (2000) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/000486740003401s22 · Cited by 15
Family-Based Treatment in Prodromal and First-Episode Psychosis
McFarlane, W. R. (2001) · Springer eBooks · doi:10.1007/978-94-010-0892-1_11 · Cited by 14
Family Intervention in First Episode Psychosis
Lepage, S. J. M. (2005) · International Journal of Systemic Therapy · doi:10.1300/j085v16n03_07 · Cited by 14
The Natural Course of Schizophrenia and Psychopathological Predictors of Outcome
Michele, V. D., & Bolino, F. (2004) · Psychopathology · doi:10.1159/000078090 · Cited by 14
The Concept of Schizophrenia: From Unity to Diversity
Häfner, H. (2014) · Advances in Psychiatry · doi:10.1155/2014/929434 · Cited by 18
Treatment resistance and other complicating factors in the management of schizophrenia
Strassnig, M., & Harvey, P. D. (2014) · CNS Spectrums · doi:10.1017/s1092852914000571 · Cited by 14
Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safety
Si, T., Zhuo, J., Turkoz, I., Mathews, M., Tan, W., & Feng, Y. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1401608 · Cited by 14
The Physician/Investigator's Obligation to Patients Participating in Research: The Case of Placebo Controlled Trials
Glass, K. C., & Waring, D. R. (2005) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2005.tb00520.x · Cited by 14
Neurodynamics and Schizophrenia Research: Editors' Introduction
Hoffman, R. E., & McGlashan, T. H. (1993) · Schizophrenia Bulletin · doi:10.1093/schbul/19.1.15 · Cited by 14
The nature of schizophrenia: signposts to prevention
McGorry, P. D. (2000) · Australian & New Zealand Journal of Psychiatry · doi:10.1046/j.1440-1614.2000.00772.x · Cited by 14
Treatment of recurrent depression
Greden, J. F. (2001) · Cited by 14
Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders
Kutcher, S., Brooks, S. J., Gardner, D. M., Honer, B., Kopala, L. C., Labelle, A., Lalonde, P., MALLA, A. K., Milliken, H., Soni, J., et al. (2005) · Neuropsychiatric Disease and Treatment · doi:10.2147/nedt.1.2.89.61042 · Cited by 14
Impact of duration of untreated psychosis in short‐term response to treatment and outcome in antipsychotic naïve first‐episode psychosis
Cavalcante, D. A., Coutinho, L., Ortiz, B. B., Noto, M. N., Cordeiro, Q., Ota, V., Belangero, S. I., Bressan, R. A., Gadelha, A., & Noto, C. D. S. (2019) · Early Intervention in Psychiatry · doi:10.1111/eip.12889 · Cited by 13
The treatment of schizophrenia: from premorbid manifestations to the first episode of psychosis
Davidson, M., Caspi, A., & Noy, S. (2005) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2005.7.1/mdavidson · Cited by 13
Mental Health Performance Measurement in Corrections
Hoge, S. K., Greifinger, R. B., Lundquist, T. G., & Mellow, J. (2008) · International Journal of Offender Therapy and Comparative Criminology · doi:10.1177/0306624x08322692 · Cited by 13
Do clinical characteristics predict the cognitive course in early‐onset schizophrenia‐spectrum disorders?
Teigset, C. M., Mohn, C., Brunborg, C., Juuhl‐Langseth, M., Holmén, A., & Rund, B. R. (2018) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12896 · Cited by 13
Evaluation of patients on sertindole treatment after failure of other antipsychotics: A retrospective analysis
Azorin, J., Murteira, S., Hansen, K., & Toumi, M. (2008) · BMC Psychiatry · doi:10.1186/1471-244x-8-16 · Cited by 13
Identification of young people at risk of psychosis
Parker, S., & Lewis, S. W. (2006) · Advances in Psychiatric Treatment · doi:10.1192/apt.12.4.249 · Cited by 16
Are We Really Impacting Duration of Untreated Psychosis and Does It Matter?
Clarke, M., McDonough, C. M., Doyle, R., & Waddington, J. L. (2016) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2016.01.002 · Cited by 13
Subjective Evaluations of Research Participation by Persons With Mental Illness
Rosen, C., Grossman, L. S., Sharma, R. P., Bell, C. C., Mullner, R., & Dove, H. W. (2007) · The Journal of Nervous and Mental Disease · doi:10.1097/01.nmd.0000253785.81700.7d · Cited by 13
Proper psychosocial rehabilitation for stabilised patients with schizophrenia: the role of new therapies
Peuskens, J. (1996) · European Neuropsychopharmacology · doi:10.1016/0924-977x(96)00011-9 · Cited by 13
Low-dose Depot Medication in Schizophrenia
Burnett, P. L., Galletly, C. A., Moyle, R., & Clark, C. R. (1993) · Schizophrenia Bulletin · doi:10.1093/schbul/19.1.155 · Cited by 13
Perspectives on Treatment Needs in Schizophrenia
Meise, U., & Fleischhacker, W. W. (1996) · The British Journal of Psychiatry · doi:10.1192/s0007125000298267 · Cited by 13
Antipsychotics and structural brain changes: could treatment adherence explain the discrepant findings?
Emsley, R. A. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231195258 · Cited by 12
Observance médicamenteuse et rechutes dans la schizophrénie : des neuroleptiques classiques aux APAP
Palazzolo, J. (2009) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2009.03.009 · Cited by 15
Cognitive deterioration and duration of untreated psychosis
Gaynor, K., Dooley, B. A., Lawlor, E., Lawoyin, L. R., & O’Callaghan, E. (2009) · Early Intervention in Psychiatry · doi:10.1111/j.1751-7893.2009.00121.x · Cited by 12
Translational Potential of Neuroimaging Genomic Analyses to Diagnosis and Treatment in Mental Disorders
Chen, J., Liu, J., & Calhoun, V. D. (2019) · Proceedings of the IEEE · doi:10.1109/jproc.2019.2913145 · Cited by 13
Early intervention in schizophrenia: three frameworks for guiding ethical inquiry
Candilis, P. J. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1412-3 · Cited by 12
The Loss of Client Agency into the Psychopharmaceutical-Industrial Complex
Murray, T. L. (2009) · Journal of Mental Health Counseling · doi:10.17744/mehc.31.4.a7g4763326541540 · Cited by 12
Predicting the onset of schizophrenia
Klosterkötter, J. (2002) · Steinkopff eBooks · doi:10.1007/978-3-642-57516-7_17 · Cited by 12
New targets for antipsychotics
JONES, H. M., & Pilowsky, L. S. (2002) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2.1.61 · Cited by 12
A review of patient outcomes in pharmacological studies from the psychiatric literature, 1966–1993
Shamoo, A. E., Irving, D. N., & LANGENBERG, P. W. (1997) · Science and Engineering Ethics · doi:10.1007/s11948-997-0043-1 · Cited by 12
Acute Pharmacological Treatment of Schizophrenia
Miyamoto, S., Stroup, T. S., Duncan, G. E., Aoba, A., & Lieberman, J. A. (2003) · Wiley eBooks · doi:10.1002/9780470987353.ch24 · Cited by 12
Duration of untreated psychosis : association with clinical and social outcomes and brain morphology in schizophrenia
Penttilä, M. (2013) · Cited by 11
Early intervention in schizophrenia patients--rationale for its implementation and practice.
Chen, E. Y. H. (1999) · PubMed · Cited by 11
Clinical Outcome of Patients With Schizophrenia Without Maintenance Treatment in a Nonindustrialized Society
Kurihara, T., Kato, M., Reverger, R., & Yagi, G. (2002) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006958 · Cited by 11
Relationship of the factor structure of psychopathology in schizophrenia to the timing of initial intervention with antipsychotics
Meagher, D. J., Quinn, J., Murphy, P. L., Kinsella, A., Mullaney, J., & Waddington, J. L. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00050-5 · Cited by 11
The long-acting depot antipsychotic drugs
Pandarakalam, J. P. (2003) · Hospital Medicine · doi:10.12968/hosp.2003.64.10.2327 · Cited by 11
Monitoring and Care of Young People at Incipient Risk of Psychosis
Yung, A. R., McGorry, P. D., McFarlane, C. A., Jackson, H. J., Patton, G. C., & Rakkar, A. (2004) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.2.1.158 · Cited by 11
Identifying Vulnerability Markers in Prodromal Patients: A Step in the Right Direction for Schizophrenia Prevention
Knowles, L., & Sharma, T. (2004) · CNS Spectrums · doi:10.1017/s1092852900002765 · Cited by 11
Are the Effects of Duration of Untreated Psychosis Socially Mediated?
Norman, R. M. G. (2014) · The Canadian Journal of Psychiatry · doi:10.1177/070674371405901004 · Cited by 12
Influence of duration of untreated psychosis on the short-term outcome of drug-free schizophrenia patients.
Philip, M., Gangadhar, B. N., Jagadisha, Velayudhan, L., & Subbakrishna, D. K. (2003) · PubMed Central · Cited by 11
Recognition and Treatment of the Pre-psychotic Phase of Psychotic Disorders
McGorry, P. D., Phillips, L., & Yung, A. R. (2001) · Springer eBooks · doi:10.1007/978-94-010-0892-1_5 · Cited by 11
Signs and Symptoms
Lieberman, J. A. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950170035005 · Cited by 11
Creatine Kinase and Enolase: Intracellular Enzymes Serving as Markers of Central Nervous System Damage in Neuropsychiatric Disorders
El‐Mallakh, R. S., Egan, M., & Wyatt, R. J. (1992) · Psychiatry · doi:10.1080/00332747.1992.11024612 · Cited by 11
Self-citation
Jung's views on causes and treatments of schizophrenia in light of current trends in cognitive neuroscience and psychotherapy research I. Aetiology and phenomenology
Silverstein, S. M. (2014) · Journal of Analytical Psychology · doi:10.1111/1468-5922.12057 · Cited by 11
Understanding Components of Duration of Untreated Psychosis and Relevance for Early Intervention Services in the Canadian Context: Comprendre les Composantes de la Durée de la Psychose Non Traitée et la Pertinence de Services D’intervention Précoce Dans le Contexte Canadien
MALLA, A. K., Dama, M. H., Iyer, S. N., Joober, R., Schmitz, N., Shah, J. L., Mansouri, B. I., Lepage, M., & Norman, R. M. G. (2021) · The Canadian Journal of Psychiatry · doi:10.1177/0706743721992679 · Cited by 10
Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
Louzã, M. R., Elkis, Ruschel, de Oliveira, I., Bressan, R. A., Belmonte-de-Abreu, P. S., Grabowski, & Appolinário (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s20589 · Cited by 10
Neuroleptic Treatment of Patients with Schizophrenia Mechanisms of Action and Clinical Significance
Wiesel, F. (1994) · The British Journal of Psychiatry · doi:10.1192/s0007125000292763 · Cited by 10
ETIOPATHOGENESIS AND TREATMENT OF PSYCHOSIS
Crow, T. J., & Harrington, C. A. (1994) · Annual Review of Medicine · doi:10.1146/annurev.med.45.1.219 · Cited by 10
Medication-Free Research With Schizophrenic Patients
LADER, M. H. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830170028003 · Cited by 10
Negative symptoms
McPhillips, M. A., & Barnes, T. R. E. (1997) · Current Opinion in Psychiatry · doi:10.1097/00001504-199701000-00007 · Cited by 10
Prodromal Symptoms and Early Detection of Schizophrenia
Häfner, H., & Maurer, K. (2005) · doi:10.1002/0470010851.ch1 · Cited by 13
How Does Untreated Psychosis Lead to Neurological Damage?
McKenzie, K. J. (2014) · The Canadian Journal of Psychiatry · doi:10.1177/070674371405901002 · Cited by 10
Beginn und Frühverlauf schizophrener Erkrankungen
Häfner, H., der Heiden, W. A., Löffler, W., Maurer, K., & Hambrecht, M. (1998) · Springer eBooks · doi:10.1007/978-3-642-72204-2_1 · Cited by 10
The Mechanisms of Persisting Disability in Schizophrenia: Imprecise Predictive Coding via Corticostriatothalamic-Cortical Loop Dysfunction
Liddle, P. F., & Sami, M. B. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.08.007 · Cited by 9

Authors: Wyatt, R. J.
Affiliations: St. Elizabeths Hospital (US)
Corresponding author: Wyatt, R. J.
Venue: Schizophrenia Bulletin
Publisher: Oxford University Press (OUP)
Published: 1991-01-01
Volume: 17
Issue: 2
Pages: 325-351
ISSN: 0586-7614 (ISSN-L)
1745-1701
DOI: 10.1093/schbul/17.2.325
OpenAlex: W2120012268
Cited by: 787
References: 73
Citations by year: 2026: 6 · 2025: 10 · 2024: 8 · 2023: 5 · 2022: 4 · 2021: 21 · 2020: 12 · 2019: 48 · 2018: 14 · 2017: 18 · 2016: 17 · 2015: 17 · 2014: 18 · 2013: 22 · 2012: 27
FWCI: 13.18
Type: journal article
Language: en
Open access: closed
Locations: Schizophrenia Bulletin (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords: schizophrenia, antipsychotic drugs
MeSH terms: Humans, Recurrence, Schizophrenia, Time Factors, Antipsychotic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Neuroleptics and the Natural Course of Schizophrenia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks